ROCO
1796
Market cap64mUSD
Nov 13, Last price
48.60TWD
Name
GeneFerm Biotechnology Co Ltd
Chart & Performance
P/E
—
P/S
3.87
EPS
—
Div Yield, %
4.12%
Shrs. gr., 5y
8.28%
Rev. gr., 5y
9.69%
Revenues
521m
-34.34%
Net income
-23m
L
CFO
8m
-95.75%
Dividend
Jul 10, 20242 TWD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
GeneFerm Biotechnology Co., Ltd. develops, manufactures, and sells fermented health care products in Taiwan and internationally. The company offers microbial fermentation products, which includes mushrooms, lactic acid bacteria, bacteria, yeast, and algae; bio fermented ingredients, such as nattomena, natto fermented powder, red yeast rice fermented powder, antrodia cinnamomea mycelia powder, cordyceps, reishi mycelia, phellinus linteus mycelia powder, armillaria mellea mycelia powder, beta-glucan powder, fruits and vegetables fermented enzyme, as well as probiotics and peptide ingredients. It also provides private label supplements; packaging equipment; microbial fermentation toll manufacturing and consulting services. The company was founded in 1988 and is headquartered in Tainan City, Taiwan.
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT | ||||||